A study of the relative bronchodilator responsiveness in smoker asthmatics

Raju, C H; Ravindranath, M

doi:10.18203/2349-3933.ijam20161086

Cited by 1 publication

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 This was in similar to reported by Jindal et al, Wimpe et al, and Raju and Ravidranath. 26,29,30 However another study by Brophy et al, reported that on addition of ipratropium, FEV1 was increased by 75% thereby reducing the hospital admission, when compared to the administration od a beta-2 stimulus alone. 31 A study by O'Driscoll et al, Rebuck et al, and Rossing et al, have reported that the patient who have severe asthma, seem to have a better reaction to addition of ipratropium bromide to salbutamol.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of relative bronchodilatation of salbutamol and ipratropium in smokers and non-smokers with asthma

Reddy¹,

Reddy²

2020

IJIRM

View full text Add to dashboard Cite

Asthma is an age old disease with breathlessness and wheezing as a part of its clinical manifestations. Adrenergic drugs are also used as bronchodilators as they have a fast action. They are also useful in improving the mucilary transport and in the reduction in the release of inflammatory mediators. Sympathetic and parasympathetic mechanisms for airway calibre control were tested on 80 patients above the age of 18 years with bronchial asthma using salbutamol (beta 2 androgenic drug) and ipratropium bromide (anticholinergic drug). The base line values in our study, of the smokers and non-smokers on Day 1, where Salbutamol was given as the primary drug with Ipratropium as the second drug showed a significant difference in the FEV1, FVC and PEFR values, while there was no significant difference in the FEV1/FVC ratio. After giving salbutamol to the maximum effect, in comparison to the base line, there was a considerable improvement in all the values in both the smokers and non-smokers. But on giving Ipratropium, there was no further substantial improvement in the values in the non-smokers, but a significant improvement was seen among the smokers. On day two, there was a significant improvement in the FEV1, FVC, FEV1/FVC and PEFR values compared to the base line values, and on giving salbutamol, there was a substantial increase in the expiration volume in both smokers and non-smokers. In case of smoker asthmatics, a combination therapy of Salbutamol and Ipratropium is more useful.

show abstract

Section: Discussionmentioning

confidence: 99%

“…25 Similar results were found in another similar study by Raju and Rajendranath. 26 Ina study by Copenhagen city heart, measured the longitudinal aspect of the FEV1 in 15 years. It was found that there was a decline of FEV1 in smokers with asthma rather than those who didn't smoke.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of relative bronchodilatation of salbutamol and ipratropium in smokers and non-smokers with asthma

Reddy¹,

Reddy²

2020

IJIRM

View full text Add to dashboard Cite

show abstract

A study of the relative bronchodilator responsiveness in smoker asthmatics

Cited by 1 publication

References 19 publications

Efficacy of relative bronchodilatation of salbutamol and ipratropium in smokers and non-smokers with asthma

Efficacy of relative bronchodilatation of salbutamol and ipratropium in smokers and non-smokers with asthma

Contact Info

Product

Resources

About